Immune cells with venetoclax for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with AML or a high-risk form of MDS.
- You have had at least one previous treatment for your leukemia, which may include chemotherapy or a stem cell transplant (if the transplant was more than 6 months ago).
- Your leukemia has certain high-risk features, such as specific genetic changes that make relapse more likely.
- You must be able to take pills and have adequate organ function (heart, liver, kidneys) as determined by blood tests and other evaluations.
- You cannot be pregnant, and if you are of childbearing age, you must agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.